BEMPEDOIC ACID BEMPEDOIC ACID WITH EZETIMIBE
Information current as at: 1 June 2026
PBAC meeting date: July 2026
Submission Details
- Brand name:
-
- Nexletol®
- Nexlizet®
- Form and strength:
-
- Tablet 180mg
- Tablet 180mg bempedoic acid with 10 mg ezetimibe
- Submission sponsor:
- SEQIRUS (AUSTRALIA) PTY LTD
- Condition/indication:
(therapeutic use) -
- Hypercholesterolaemia
- Listing requested:
- To request listing of bempedoic acid, as monotherapy and in combination with ezetimibe, for the treatment of adult patients with hypercholesterolaemia (heterozygous familial and non-familial) at high risk of a first cardiovascular event or with established symptomatic atherosclerotic cardiovascular disease who have statin intolerance or are on maximally tolerated statin therapy, and despite treatment with ezetimibe, continue to have low-density lipoprotein cholesterol (LDL-C) levels greater than 1.8 mmol/L.
- Funding program:
- PBS General Schedule
- Request authority level:
- Authority Required (STREAMLINED)
- PBAC Submission type:
- New PBS listing (–)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - July 2026 PBAC meeting
-
Opportunity for consumer comment: - Open 25/03/2026 and close 20/05/2026 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Pending PBAC outcome (see PBAC Outcomes)
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID
1214
Page last updated
31 May 2026
v.9.19